Controlled release processes

The rationale for the development of such fibers is demonstrated by their appHcation in the medical field, notably hemoperfusion, where cartridges loaded with activated charcoal-filled hoUow fiber contact blood. Low molecular weight body wastes diffuse through the fiber walls and are absorbed in the fiber core. In such processes, the blood does not contact the active sorbent direcdy, but faces the nontoxic, blood compatible membrane (see Controlled RELEASE TECHNOLOGY, pharmaceutical). Other uses include waste industrial appHcations as general as chromates and phosphates and as specific as radioactive/nuclear materials. 

In cases of all but intravenous adininistration, dosage forms must make the active moiety available for absorption, ie, for dmg release. This influences the bioavailabiUty and the dmg s pharmacokinetic profile. Ideally the dmg is made available to the blood for distribution and elimination at a rate equal to those processes. Through technological developments dmg product design can achieve release, absorption, and elimination rates resulting in durations of activity of 8—12 hours, ie, prolonged action/controlled release dmg products (21,22). Such products improve the compliance rate of dmg usage by patients. 

The state of Texas controls chemical process ha2ards through its statute that estabUshed the Texas Air Control Board in 1965. In 1985, guidelines were estabUshed for evaluations of community impact of releases of 46 toxic chemicals, if Texas decides that a disaster potential exists (26). 

Meat Products. Citric acid is used in cured meat products to increase the effectiveness of the antioxidant preservatives, as a processing aid, and a texture modifier. It is often encapsulated and released at a specific temperature from a controlled release matrix. 

Fuji Peel-Apart Film FP-100. In 1984 Fuji introduced FP-lOO, a peel-apart instant color film rated at ISO 100. The FP-lOO system uses a dye-release process similar to that used in the Fuji integral films. Figure 16b is a schematic cross section of FP-100, and Figure 11b (on the colored plate) is a micrograph of the unprocessed film in cross section. The negative stmcture includes a spacer layer between the red-sensitive layer and the cyan dye-releaser layer that it controls, similar to that shown in the FI-800 stmcture, but there are no spacers between the other emulsions and corresponding dye-releaser layers. 

Oxamide is produced commercially by Ube Industries, Ltd. (Japan) and a pilot process is being operated by Enichem (Italy). It is not produced domestically as a commercial fertilizer, although it was the subject of much research and development activity by the Tennessee Valley Authority s (TVA) National Fertilizer Research and Development Center. It is made in small quantities for industrial use by AUied Chemical, Hummel Chemical Co., and United Guardian, Inc. Oxamide has appHcation as a controlled release nitrogen source for the turf and specialty agricultural markets. 

In swelling-controlled systems, glassy hydrogels ia particular, the release process is a combination of the diffusion of water iato the system and dmg from the system. Empirically, release from these systems may be expressed as (83) ... 

Each employer must address what actions employees are to take when there is an unwanted release of highly hazardous chemicals. Emergency preparedness is the employer s third line of defense that will be relied on along with the second line of defense, which is to control the release of chemicals. Control releases and emergency preparedness will take place when the first line of defense to operate and maintain the process and contain the chemicals fails to stop the release. In preparing for an emergency chemical release, employers will need to decide the following ... 

The combustion processes which control the critical depressurization rate are not understood. Landers (LI) and Von Elbe (VI) have tired to derive an expression for the critical depressurization rate, but the transient combustion model they used is far too simplified to predict the effects shown in Figs. 24 and 25. One possible explanation for these large variations would be that heat-release processes within the solid phase are important. From light-emission measurements during depressurization, Ciepluch observed that it was much easier to eliminate light emission than to terminate combustion (i.e., approximately 12,000 psi/sec produced light emission, compared with 100,000 psi/sec for termination). 

Microspheres and microcapsules of lactide/glycolide polymers have received the most attention in recent years. Generally, three microencapsulation methods have been employed to afford controlled release formulations suitable for parenteral injection (1) solvent evaporation, (2) phase separation, and (3) fluidized bed coating. Each of these processes requires lactide/glycolide polymer soluble in an organic solvent. 

Polylactic acid (PLA) has been produced for many years as a high-value material for use in medical applications such as dissolvable stitches and controlled release devices, because of the high production costs. The very low toxicity and biodegradability within the body made PLA the polymer of choice for such applications. In theory PLA should be relatively simple to produce by simple condensation polymerization of lactic acid. Unfortunately, in practice, a competing depolymerization process takes place to produce the cyclic lactide (Scheme 6.10). As the degree of polymerization increases the rate slows down until the rates of depolymerization and polymerization are the same. This equilibrium is achieved before commercially useful molecular weights of PLA have been formed. 

Apply controlled release Inhibit processes leading to... 

Root exudation of extraordinary high amounts of specific carboxy lutes (e.g ci-u-ate, malate. oxalate, pbytosiderophores) in response to nutritional deficiency stress or Al toxicity in some plant species cannot simply be attributed to diffusion processes. The controlled release of these compounds, involved in mobilization of mineral nutrients and in detoxification of Al. may be mediated by more specific mechanisms. Inhibitory effects by exogenous application of various anion chan-... 

Barnes CE, Cochran JK (1993) Uranium geochemistry in estuarine sediments Controls on removal and release processes. Geochim Cosmochim Acta 57 555-569 Berkman PA, Foreman DW, Mitchell JC, Liptak RJ (1992) Scallop shell mineralogy and crystalline characteristics Proxy records for interpreting Antarctic nearshore marine hydrochemical variability. Contrib Antartic Research 57 27-38... 

Generate or release gases into selected areas of the fluid polymers (used almost exclusively to control foaming processes). 

A novel polymerized vesicular system for controlled release, which contains a cyclic a-alkoxyacrylate as the polymerizable group on the amphiphilic structure, has been developed. These lipids can be easily polymerized through a free radical process. It has been shown that polymerization improves the stabilities of the synthetic vesicles. In the aqueous system the cyclic acrylate group, which connects the polymerized chain and the amphiphilic structure, can be slowly hydrolyzed to separate the polymer chain and the vesicular system and generate a water-soluble biodegradable polymer. Furthermore, in order to retain the fluidity and to prepare the polymerized vesicles directly from prev lymerized lipids, a hydrophilic spacer has been introduced. 

In the past, many of the terms used to refer to therapeutic systems of controlled and sustained release have been used in an inconsistent and confusing manner. Although descriptive terms such as timed release and prolonged release give excellent manufacturer identification, they can be confusing to health care practitioners. For the purposes of this chapter, sustained release and controlled release will represent separate delivery processes. Sustained release constitutes any dosage form that provides medication... 

---